



Date: 30<sup>th</sup> April, 2026

To The Listing Department <b>National Stock Exchange of India Limited</b> Exchange Plaza, Bandra – Kurla Complex Bandra (East) Mumbai – 400 051 <b>Stock Code : INDOCO</b>	To The Listing Department <b>Bombay Stock Exchange Limited</b> Floor 25, P. J. Towers, Dalal Street, Mumbai – 400 001 <b>Stock Code : 532612</b>
---	--

Dear Sir/Madam,

**Subject: Press Release- Approval of Agreement to Transfer Business by Indoco Remedies Limited**

We enclose a copy of Press Release issued by the Company in respect to the captioned subject.

Kindly take note of the same.

**Thanking you,  
Yours faithfully,  
For Indoco Remedies Limited**



**Ramanathan Hariharan  
Company Secretary & Head Legal**



## PRESS RELEASE

### **Indoco Remedies announces strategic transfer of its ophthalmic division to Sunways India**

**Mumbai, April 30, 2026:** Indoco Remedies Ltd. has announced that in the Board Meeting conducted today, it has considered and approved the transfer of the Company's ophthalmic business ("Ophthalmic Division") in the territories of India and agreed territories in Africa ("Territories") on such terms and conditions as detailed in the Agreement to Transfer Business ("ATB") to Sunways (India) Private Limited.

For Sunways (India) Private Limited, the proposed transaction is expected to strengthen its ophthalmology platform by adding an established operating business and complementing its existing product portfolio and manufacturing capabilities. Sunways (India) Private Limited is the flagship company of the Sunways group and manufactures and markets a range of formulations in the niche market of ophthalmology and ENT. It manufactures a wide range of sterile ophthalmic and ENT products and operates within a broader group platform that also includes manufacturing capability for oral medications and sterile preparations.

Commenting on this development, **Ms. Aditi Panandikar, Managing Director – Indoco Remedies Ltd.** said, "This divestment is an important step in sharpening our focus on core therapeutic areas with stronger potential. We are confident that Sunways will further build on the strengths of the ophthalmic division, leveraging its core competencies across markets. At Indoco, we will continue to invest in innovation, quality and operational excellence, creating long-term value for our stakeholders and the communities we serve."

Commenting on the transaction, **Mr. Bhadresh Shroff, Director - Sunways (India) Private Limited** said, "This transaction is aligned with our strategy of strengthening our ophthalmology business through the acquisition of an established operating portfolio. We believe the transferred business offers a strong strategic fit with our existing platform and capabilities, and we look forward to ensuring a smooth transition and continuity for customers, products and other stakeholders."

### **About Indoco Remedies Limited:**

Indoco is a fully integrated, research-oriented pharmaceutical company with a strong global presence. The Company's turnover is US\$ 180 million with a human capital of over 6000 employees, including over 400 skilled scientists and field staff who are the strength of the organization.

The Company has 10 manufacturing facilities, 6 for FDFs and 4 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 106 million prescriptions annually from over 2,40,000 doctors belonging to various specialties. Indoco has 10 domestic marketing divisions, a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infectives, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management, Gynaecology, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensoform, SensodentKF, Aloja, Glychek, Kidodent, Subital, Rexidin, MCBM 69, Methycal, Dropizin, Noxa, Homide, Cal-Aid, Ninaf, Cital-Uti, Otorex, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.

For more details on Indoco, you may visit [www.indoco.com](http://www.indoco.com)

#### **For Media enquiries please contact:**

Tel. | +91 22 62871000

E-mail: [corpcom@indoco.com](mailto:corpcom@indoco.com)

### **About Sunways**

Sunways (India) Private Limited was incorporated in 1951 with an unflinching determination and commitment to provide the vital services of Health Care in India. It is a medium sized Pharmaceutical Company, manufacturing and marketing a wide range of formulations in the niche market of Ophthalmology and ENT.

Over the last seven decades, a comprehensive interaction with the ophthalmic faculty in the country through the field staff and senior management, the Company has been groomed to manufacture and provide top quality and affordable medicines in the area of Ophthalmology.

#### **For Media enquiries please contact:**

Tel. | +91 61069999

E-mail: [corpcommunication@sunways.com](mailto:corpcommunication@sunways.com)